Medicare Law Does Not Require Legislative Change, McClellan Says
This article was originally published in The Pink Sheet Daily
Legislation would slow implementation of the drug benefit, which is a primary goal of CMS, McClellan says. Overall savings will offset additional costs that the states take on under the federal “clawback,” he notes.
You may also be interested in...
Increased flexibility in controlling drug costs will be required for states to maintain their bargaining power following the shift of “dual eligibles” to Medicare in 2006, Oklahoma Medicaid director says.
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.